Clinical Trial Update: Triple Combination DAAs for Treating HCV GT1b Subjects [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a triple direct-acting antiviral regimen for chronic hepatitis C infection (genotype 1b) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: Humanity and Health Research Centre | Conditions: Chronic Hepatitis C Infection | Phase 2 | Status: WITHDRAWN